TX-MOBIL-1
To celebrate the 50th anniversary of Mobil 1™ motor oil, this year the brand will showcase more than 40 iconic, specially-designed liveries and paint schemes on the track throughout the 2024 motorsports season.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240315781564/en/
These liveries – which will be seen within IMSA, WEC, Formula 1, NASCAR, NHRA, MotoGP and more – use distinct design elements, including anniversary gold, both signifying 50 years of the Mobil 1 brand and embodying the dynamic relationships between Mobil 1 and its collaborators. Each paint scheme reflects the spirit of the Mobil 1 brand and an ongoing commitment to growing and maintaining meaningful track-to-road relationships, which is at the heart and soul of the brand.
Mobil 1 motor oils have long been the choice for preeminent race teams competing in the most demanding and popular motorsports series around the globe. Today, Mobil 1 synthetic motor oil continues to be relied upon for its ability to deliver exceptional engine performance and protection under some of the most extreme conditions. Automotive technicians, race car drivers, team owners, and some of the world’s leading automotive manufacturers can speak to the advanced technology of Mobil 1 lubricants.
“We are thrilled to bring these special paint schemes to life for such a historic anniversary of the Mobil 1 brand,” said Robert Shearer, Director of Global Sponsorships on behalf of Mobil 1. “These liveries exemplify our collaborations in lubricant innovation in the world of motorsports. Together, we’ve crafted livery designs that not only pay homage to the 50-year legacy of the Mobil 1 brand, but also capture the essence of speed, performance and teamwork. We can’t wait for fans to join us in the love of racing and witness the culmination of our collaborative efforts on the racetrack throughout the rest of the year.”
At Mobil 1 Twelve Hours of Sebring Presented by Cadillac, golden liveries will hit the track for teams and OEMs, including Vasser Sullivan Racing (Lexus Racing), Cadillac Racing, Corvette Racing by Pratt Miller Motorsports, Kellymoss with Riley (Porsche Motorsport North America), and Porsche Penske Motorsport.
With more added throughout the season, initial 50th anniversary liveries and iconography will be seen at the following upcoming race series on sponsored teams:
- Oracle Red Bull Racing (Formula 1)
- Stewart-Haas Racing (NASCAR Cup Series)
- 23XI Racing (NASCAR Cup Series)
- Tony Stewart Racing (NHRA)
- Red Bull KTM (MotoGP)
- Porsche Penske Motorsport (WEC and IMSA)
- TAG Heuer Porsche Formula E Team (Formula E)
- Mobil 1 Porsche SuperCup
- At the Pikes Peak International Hill Climb with BBI Autosport
In continuing to commemorate the 50th anniversary, fans should also look for a short film featuring former Formula 1 racer & Oracle Red Bull Racing ambassador, David Coulthard, who guides the audience through the Mobil 1 brand’s evolution, collaborations, and achievements. The video is available for viewing here.
Additional initiatives across partnerships, motorsports, and events will be shared through the year as the brand continues to celebrate its legacy and what's next. For coverage of Mobil 1 Twelve Hours of Sebring Presented by Cadillac as well as upcoming gold liveries and paint schemes, visit @mobil1racing on Instagram and X all year-long.
About Mobil 1
For 50 years, Mobil 1 has been trusted by drivers to keep their engines running longer. Our products combine the latest technology and innovation to exceed the toughest standards of vehicle manufacturers and tuning shops—so consumers can get the most out of their time behind the wheel, both on the road and on the track. Turn every day into an adventure with Mobil 1, the world’s leading synthetic motor oil brand. Learn more at www.mobil1.us or and follow @Mobil1Racing on Instagram and X. Join us. For the love of driving.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240315781564/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom